


# The Institutional Biosafety Committee



## **The IBC is comprised of multiple members:**


- A Biosafety officer
- A Chair and expertise members
- Administrative staff

These roles, along with other on campus departments, work together to support research laboratories and maintain compliance.



## **The Institutional Biosafety Committee (IBC) will review:**


- Policies and Procedures
- Training
- Programs
- Containment
- Oversee research projects involving biological materials




## The IBC Works In Harmony With:

- UAWC
- OSP
- IRB
- And other institutional  
committees and  
departments

IBC approval does not  
waive the requirement for  
independent review by  
other research  
compliance committees.




## The IBC will ensure that all research adheres to:

- NYU's Institutional Biosafety Policy and Procedures
  - *NIH Guidelines* for Research Involving Recombinant Synthetic Nucleic Acid Molecules (*NIH Guidelines*)
  - Biosafety in Microbiological and Biomedical Laboratories (BMBL).
  - Other federal, state, and local regulations
- 



# IBC Responsibilities

## In a nutshell, what will NYU's IBC review?

1. Research involving recombinant or synthetic nucleic acid molecules (rsNA) for conformity with the *NIH Guidelines*
  2. Potential risk to public health and environment
  3. Biohazardous Materials
  4. Genetically Modified Organisms (GMOs)
  5. Any organism, agent or toxin requiring federal permits
  6. Human Gene Transfer
  7. Highly Infectious (Risk Group 3 or 4) and USDA/CDC regulated Select Agents/Toxins with stipulations
- 



# Research Classifications & Approval Process



**SECTION III-A (Major Actions):** Requires IBC and NIH Director review **before** initiation of experiments

- ❑ A project involving making staphylococcus aureus resistant to doxycycline

**SECTION III-B:** Requires IBC approval and NIH review **before** initiation of experiments

- ❑ Cloning Botulinum toxin into E. coli

**SECTION III-C:** Requires IBC, IRB approvals and RAC\* review **before** initiation of experiments

- ❑ Human gene transfer experiments

*\*RAC is currently no longer accepting new human gene transfer protocols as the NIH looks to streamline the new review process*

**SECTION III-D:** Requires IBC and UAWC approval **before** initiation of experiments

- ❑ Using an HIV viral vector to correct sickle cell disease in transgenic mice

**SECTION III-E:** Requires IBC notice **simultaneous** with initiation (i.e. submission of complete registration)

- ❑ Generating transgenic rodents using AAV viral vector

**SECTION III-F:** Requires IBC notice **simultaneous** with initiation (i.e. submission of complete registration)

- ❑ Purchase of transgenic mice

**Non-Recombinant Synthetic:** Requires IBC notice **simultaneous** with initiation

- ❑ Collecting water samples from Burkina Faso to determine the microbiome

IBC  
Approval



- BL-2 Projects
- Animal experiments
- Insect experiments
- Plant experiments
- Human Gene Transfer
- Large Scale Production

VS

Administrative  
(BSO) Approval



- BL-1 projects
- Minor amendments
- non-rsNA registrations
- Exempt experiments under the NIH Guidelines

## When the PI is the prime awardee:

- Research involving Risk Group 2 or below agents ( or RG3 agents that can be used at Biosafety Level 2)
  - NYUWS will serve as the compliance committee of record
  
- Research involving Risk Group 3, 4 or Restricted Agents (including Select Agents and Toxins)
  - PI will need to submit a NYU IBC registration and supporting documents used to verify outside research
  - Receive approval from the “Non-NYU institutions” who must serve as the compliance committee of record

## A copy of the approval letter will be sent to the appropriate Pre/Post Awards team members

- Funds may be released **after** receiving an IBC Approval letter for III-A to III-D projects.
  - ❑ Projects under these classifications are highly monitored by NIH and other federal agencies

## Lapse in approval notification process

- AVP for Sponsored Research, Post Award Administration, Post award team members will be notified of issues of non-compliance particularly III-A to III-D projects
  - ❑ For III-A to III-D experiments: Renewal registration must be approved ***before the expiration date*** of the current registration in order to avoid interruption of activities.

# What key words should you to look for?

- Recombinant
- Transgenic
- Animal
- NIH/CDC
- DNA
- Virus
- Viral Vector
- Pathogen
- Nucleic Acids
- Gene Therapy
- Human Tissue
- Bacteria
- Phages
- Mycoplasmas
- Fungi
- Parasites
- Prions
- Rickettsias
- Toxins
- Plant
- Insect
- Drosophila
- Gene
- Construct
- Primer
- Polymerase Chain Reaction (PCR)
- Sequence
- Genome
- Cell/cell lines
- CRISPR/Cas9, Cas12a
- *In vivo*
- *In vitro*
- Knock out
- Knock In
- RNA/ DNA
- GFP



NYU

Environmental  
Health and Safety

# Environmental Health and Safety

Contact us with questions or concerns

## IBC/Biosafety Contact

Address: 10 Astor Place, 6<sup>th</sup> Floor  
NY, NY, 10003

Kechia Hester - Institutional Biosafety Officer  
Phone: 212-998-1440

Nicole Davis - IBC Coordinator/Research  
Safety Specialist  
Phone: 212-998-1418

Email: [IBC@nyu.edu](mailto:IBC@nyu.edu)

